Actively Recruiting

Phase 3
Age: 18Years - 75Years
All Genders
NCT06499857

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Led by University of Chicago · Updated on 2025-11-14

200

Participants Needed

2

Research Sites

163 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of the study is to learn how a weight loss medication called semaglutide, which is used to treat obesity, in addition to standard AF treatment might affect AF, atrial fibrillation severity, and whether it changes the risk of atrial fibrillation recurring after standard AF treatments.

CONDITIONS

Official Title

Semaglutide for Metabolic Intervention and Adipose Loss to Treat Atrial Fibrillation

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 to 75 years
  • Body mass index (BMI) of 30 kg/m2 or higher
  • Diagnosed with paroxysmal or persistent atrial fibrillation
  • Scheduled for catheter ablation within 1 year or not expected to have ablation within 1 year
  • Able to give informed consent
  • Patients with type 2 diabetes mellitus with HbA1c less than or equal to 10%
  • Patients on basal insulin only or oral diabetes medications or both
  • Patients on stable doses of SGLT2 inhibitors or thiazolidinediones for at least 6 months
  • Women of child-bearing potential must use appropriate contraception
  • Patients prescribed amiodarone monitored for liver and thyroid function every 6 months
Not Eligible

You will not qualify if you...

  • Current or recent (within 90 days) use of GLP-1 receptor agonists or DPP4 inhibitors
  • Current or recent (within 90 days) use of antiobesity medications
  • Weight change greater than 5 kg in the 30 days before screening
  • History of bariatric surgery
  • Diagnosis of type 1 diabetes mellitus
  • Current use of prandial insulin
  • Hospitalization for unstable angina or transient ischemic attack within 30 days before screening
  • Pulmonary embolism within 90 days before screening
  • Myocardial infarction, stroke, or similar events within 90 months before screening
  • Uncontrolled thyroid disease with TSH outside 0.4 to 10.0 mIU/L
  • Active cancer
  • Participation in another investigational study or use of investigational drugs within 90 days
  • Inability to follow study procedures
  • Acute pancreatitis within 180 days before screening
  • History or presence of chronic pancreatitis
  • Chronic kidney disease stage 4 with GFR less than 30 ml/min
  • Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
  • Serious allergic reaction to semaglutide or its ingredients
  • Chronic inflammatory conditions requiring immunosuppression or glucocorticoids
  • Previous participation in this trial
  • Pregnant, breastfeeding, or planning pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

The University of Arizona College of Medicine- Phoenix

Phoenix, Arizona, United States, 85004

Not Yet Recruiting

2

University of Chicago

Chicago, Illinois, United States, 60637

Actively Recruiting

Loading map...

Research Team

S

Silvana Pannain, MD

CONTACT

A

Andrew Beaser, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here